MedTrace Logo

A Study of Duloxetine in Patients With Osteoarthritis Knee Pain

NCT00945945 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 424

Last updated 2011-03-08

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to determine if duloxetine 60 mg once daily (QD) reduces pain severity in patients with osteoarthritis (OA) knee pain compared with placebo.

Conditions

  • Osteoarthritis Knee Pain

Interventions

DRUG

Duloxetine (DLX)

dose daily by mouth

DRUG

Placebo (PLA)

Placebo Comparator daily by mouth

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States
  • Germany
  • Greece
  • Puerto Rico
  • Romania
  • Russia
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00945945 on ClinicalTrials.gov